Schrödinger Receives Clinical-Stage Milestone Payment from Sanofi Collaboration

April 8, 2019 Off By BusinessWire

NEW YORK–(BUSINESS WIRE)–Schrödinger
today announced receipt of a milestone payment from Sanofi
(EURONEXT: SAN, NASDAQ: SNY) to mark the advancement into the clinic of
an autoimmune therapy discovered as part of a multi-year, multi-target
collaboration between the two companies.

Under the terms of the collaboration, Schrödinger provides advanced
molecular simulation and computational design expertise to Sanofi across
multiple stages of drug discovery, from target analysis and lead
optimization to identification of a development candidate. The companies
are currently advancing programs in oncology and autoimmune disease.

“We’re delighted to see this program move into the clinic and we look
forward to continued collaboration with Sanofi in order to accelerate
the development of breakthrough treatments with the potential to address
unmet medical needs in cancer and autoimmune diseases,” said Karen
Akinsanya, Ph.D., Schrödinger’s chief biomedical scientist.

The work with Sanofi is one of several partnerships Schrödinger has
established with leading biotech and pharmaceutical companies around the
world. These collaborations leverage Schrödinger’s physics-based
computational platform to enable rapid iterations of design and analysis
of potential therapeutic compounds. Such collaborations have already led
to several clinical-stage assets and two FDA-approved oncology drugs.
More than two dozen additional
programs are moving through discovery and development, in
indications ranging from metabolic disorders to neurodegenerative
diseases.

About Schrödinger
Schrödinger has a substantial and growing
global business, licensing its industry-leading computational platform
to pharmaceutical, biotechnology, chemical, and electronics companies to
accelerate R&D in both drug discovery and materials design. Schrödinger
has built a robust pipeline of therapeutic assets, held both internally
and in partnerships, and has co-founded leading biotech companies,
including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s
significant and ongoing investment in basic research continues to drive
advances in its computational platform. Founded in 1990, Schrödinger has
nearly 400 employees in its New York City headquarters and around the
world. Visit schrodinger.com
for more information.